Rani Therapeutics Holdings (RANI) Change in Accured Expenses (2020 - 2026)

Rani Therapeutics Holdings' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $763000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 348.82% year-over-year to $763000.0 in Q1 2026; TTM through Mar 2026 was $3.8 million, a 1137.64% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 809.71% from the prior year.
• Change in Accured Expenses retreated to $763000.0 in Q1 2026 per RANI's latest filing, from $3.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.2 million in Q4 2025 and bottomed at -$2.2 million in Q4 2023.
• The 5-year median for Change in Accured Expenses is $323000.0 (2023), against an average of $256588.2.
• Across the five-year window, Change in Accured Expenses sank 693.67% in 2024 and jumped 998.96% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$1.8 million in 2022, then retreated by 21.46% to -$2.2 million in 2023, then soared by 113.33% to $289000.0 in 2024, then soared by 998.96% to $3.2 million in 2025, then plunged by 75.98% to $763000.0 in 2026.
• Per Business Quant, the three latest RANI Change in Accured Expenses figures stand at $763000.0 (Q1 2026), $3.2 million (Q4 2025), and -$550000.0 (Q3 2025).